Sustiva DMP 266 non-nucleoside reverse transcriptase inhibitor data

DuPont Merck reported findings from Phase III testing of Sustiva, its non-nucleoside RT blocker, at the Interscience Conference on Antimicrobial Agents and Chemotherapy.

Read the full 231 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE